{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:24:41Z","timestamp":1793690681191,"version":"4.5.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>A novel PCM1-FGFR1 gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia. Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic remission.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002308","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T15:40:04Z","timestamp":1594395604000},"page":"3136-3140","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia"],"prefix":"10.1182","volume":"4","author":[{"given":"Monica","family":"Kasbekar","sequence":"first","affiliation":[{"name":"Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Dal Cin","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Burke","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Connolly","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Foster","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Macrae","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"McAfee","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"McGregor","sequence":"first","affiliation":[{"name":"Cancer Center, Newton-Wellesley Hospital, Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Narayan","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aura Y.","family":"Ramos","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina T.","family":"Som","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Vartanian","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb S.","family":"Friedman","sequence":"first","affiliation":[{"name":"Cancer Center, Newton-Wellesley Hospital, Newton, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim A.","family":"Benhadji","sequence":"first","affiliation":[{"name":"Taiho Oncology, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela S.","family":"Hobbs","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"issue":"20","key":"2020071011395760400_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463]","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020071011395760400_B2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020071011395760400_B3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"issue":"5","key":"2020071011395760400_B4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2009.021675","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","volume":"95","author":"Bain","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2020071011395760400_B5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"9","key":"2020071011395760400_B6","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"2020071011395760400_B7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.5858\/arpa.2016-0223-RA","article-title":"Blood and bone marrow evaluation for eosinophilia","volume":"140","author":"Boyer","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2020071011395760400_B8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2009.01.001","article-title":"Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders","volume":"23","author":"Valent","year":"2009","journal-title":"Blood Rev"},{"issue":"3","key":"2020071011395760400_B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2015.04.002","article-title":"Spectrum of eosinophilic end-organ manifestations","volume":"35","author":"Akuthota","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"2020071011395760400_B10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ijlh.12057","article-title":"Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review","volume":"35","author":"Savage","year":"2013","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"2020071011395760400_B11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"issue":"2","key":"2020071011395760400_B12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gcc.1177","article-title":"Identification of four new translocations involving FGFR1 in myeloid disorders","volume":"32","author":"Sohal","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"2020071011395760400_B13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020071011395760400_B14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"issue":"4","key":"2020071011395760400_B15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000484077","article-title":"A novel PCM1-PDGFRB fusion in a patient with a chronic myeloproliferative neoplasm and an ins(8;5)","volume":"138","author":"Ghazzawi","year":"2017","journal-title":"Acta Haematol"},{"issue":"9","key":"2020071011395760400_B16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"2020071011395760400_B17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1535-6108(04)00053-4","article-title":"Distinct stem cell myeloproliferative\/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations","volume":"5","author":"Roumiantsev","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"2020071011395760400_B18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod Pathol"},{"issue":"8","key":"2020071011395760400_B19","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"issue":"3","key":"2020071011395760400_B20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2020071011395760400_B21","first-page":"v100","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors","volume-title":"Ann Oncol","author":"Meric-Bernstam","year":"2018"},{"issue":"12","key":"2020071011395760400_B22","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2020071011395760400_B23","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","article-title":"Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","volume":"29","author":"Verstovsek","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3136\/1748293\/advancesadv2020002308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3136\/1748293\/advancesadv2020002308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T15:40:20Z","timestamp":1594395620000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3136\/461289\/Targeted-FGFR-inhibition-results-in-a-durable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002308","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}